Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh developed a new way to profile brain cancers in children.
Cervical cancer diagnoses among rural U.S. women have been increasing since 2012, after years of decreases, according to research from MUSC Hollings Cancer Center and the University of Texas MD Anderson Cancer Center.
The American College of Radiology Lung Cancer Screening Registry is expanding and will evolve into the Early Lung Cancer Detection Registry in late 2025.
Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
In a phase I study, rhenium obisbemeda (186RNL)—an investigational drug developed at the University of Texas Health Science Center at San Antonio—more than doubled median survival and progression-free time, compared with standard median survival and progression rates.
The Wistar Institute’s Paul M. Lieberman and his lab identified and tested a method for targeting certain cancers caused by Epstein-Barr Virus.
Researchers at the University of Pittsburgh have identified a trigger of high-grade serous ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.
Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.
UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.
